A detailed history of Gsa Capital Partners LLP transactions in Altimmune, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 488,125 shares of ALT stock, worth $3.85 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
488,125
Previous 51,153 854.25%
Holding current value
$3.85 Million
Previous $520,000 524.23%
% of portfolio
0.23%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$5.91 - $10.23 $2.58 Million - $4.47 Million
436,972 Added 854.25%
488,125 $3.25 Million
Q1 2024

May 03, 2024

SELL
$8.22 - $13.81 $1.3 Million - $2.19 Million
-158,309 Reduced 75.58%
51,153 $520,000
Q4 2023

Feb 16, 2024

SELL
$2.14 - $11.62 $505,908 - $2.75 Million
-236,406 Reduced 53.02%
209,462 $2.36 Million
Q3 2023

Nov 15, 2023

BUY
$2.4 - $3.45 $647,222 - $930,382
269,676 Added 153.06%
445,868 $1.16 Million
Q2 2023

Aug 14, 2023

SELL
$3.45 - $5.97 $826,833 - $1.43 Million
-239,662 Reduced 57.63%
176,192 $621,000
Q1 2023

May 12, 2023

BUY
$4.19 - $16.83 $1.57 Million - $6.3 Million
374,233 Added 899.14%
415,854 $1.75 Million
Q4 2022

Feb 13, 2023

SELL
$8.74 - $16.45 $8,740 - $16,450
-1,000 Reduced 2.35%
41,621 $685,000
Q3 2022

Nov 14, 2022

SELL
$10.67 - $22.41 $750,058 - $1.58 Million
-70,296 Reduced 62.25%
42,621 $544,000
Q2 2022

Aug 09, 2022

BUY
$3.94 - $11.77 $328,729 - $982,018
83,434 Added 282.99%
112,917 $1.32 Million
Q1 2022

May 11, 2022

SELL
$5.9 - $9.45 $115,132 - $184,407
-19,514 Reduced 39.83%
29,483 $180,000
Q4 2021

Feb 14, 2022

BUY
$8.69 - $12.48 $425,783 - $611,482
48,997 New
48,997 $449,000
Q1 2021

May 10, 2021

SELL
$12.71 - $24.31 $545,576 - $1.04 Million
-42,925 Closed
0 $0
Q4 2020

Feb 03, 2021

BUY
$7.84 - $14.22 $336,532 - $610,393
42,925 New
42,925 $484,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $386M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.